Microbiologic consequences of new approaches to managing hematologic malignancies

Reviews in Clinical and Experimental Hematology

Volumn 9, Issue 2, 2005, Pages

  Blijlevens, Nicole M A ^a   Donnelly, J Peter ^a   De Pauw, Ben E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; FLUCONAZOLE; FLUDARABINE; METHOTREXATE; MONOCLONAL ANTIBODY; PENTOSTATIN; RITUXIMAB; VORICONAZOLE;

ALLOGENEIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; HEMATOLOGIC MALIGNANCY; INCIDENCE; INFECTION COMPLICATION; INFECTION RISK; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MYCOSIS; NEUTROPENIC ENTEROCOLITIS; OPPORTUNISTIC INFECTION; REVIEW; VIRUS INFECTION;

EID: 33744959487     PISSN: 1825151X     EISSN: 1825151X     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Elting LS, Cooksley C, Chambers M, et al. The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer, 98: 1531-1539, 2003.
2. Cutler C, Li S, Kim HT, et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant, 11: 383-388, 2005.
3. Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol, 19: 2201-2205, 2001.
4. Sonis ST, Elting LS, Keefe DM, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer, 100 (9 Suppl.): 1995-2025, 2004.
5. Wardley AM, Jayson GC, Swindell R, et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haematopoietic progenitor rescue. Br J Haematol, 110: 292-299, 2000.
6. Robien K, Schubert MM, Bruemmer B, et al. Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol, 22: 1268-1275, 2004.
7. Albertioni F, Rask C, Schroeder H, Peterson C. Monitoring of methotrexate and 7 hydroxymethotrexate in saliva from children with acute lymphoblastic leukemia receiving high-dose consolidation treatment: relation to oral mucositis. Anticancer Drugs, 8: 119-124, 1997.
8. Cutler C, Li S, Kim HT, et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant, 11: 383-388, 2005.
9. Blijlevens NMA, Donnelly JP, De Pauw BE. Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for hematological malignancy: an overview. Bone Marrow Transplant, 25: 1269-1278, 2000.
10. Ruescher TJ, Sodeifi A, Scrivani SJ, et al. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 82: 2275-2281, 1998.
11. Cordonnier C, Buzyn A, Leverger G, et al. Epidemiology and risk factors for Gram-Positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis, 36: 149-158, 2003.
12. Gassas A, Grant R, Richardson S, et al. Predictors of viridans streptococcal shock syndrome in bacteremic children with cancer and stem-cell transplant recipients. J Clin Oncol, 22: 1222-1227, 2004.
13. Cunningham SC, Fakhry K, Bass BL, Napolitano LM. Neutropenic enterocolitis in adults: case series and review of the literature. Dig Dis Sci 50: 215-220, 2005.
14. Cartoni C, Dragoni F, Micozzi A, et al. Neutropenic enterocolitis in patients with acute leukemia: prognostic significance of bowel wall thickening detected by ultrasonography. J Clin Oncol, 19: 756-761, 2001.
15. Camera A, Andretta C, Villa MR, et al. Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult acute myeloid leukemia. Hematol J, 4: 346-350, 2003.
16. Blijlevens NM, Donnelly JP, de Pauw BE. Impaired gut function as risk factor for invasive candidiasis in neutropenic patients. Br J Haematol, 117: 259-264, 2002.
17. Martino R, Subira M, Rovira M, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol, 116: 475-482, 2002.
18. Martino P, Girmenia C, Venditti M, et al. Candida colonization and systemic infection in neutropenic patients. Cancer, 64: 2030-2034, 1989.
19. Guiot HFI, Fibbe WE, van 't Wout JW. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis, 18: 525-532, 1994.
20. Junghanss C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant, 8: 512-520, 2002.
21. Hori A, Kami M, Kim SW, et al. Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation. Biol Blood Marrow Transplant, 10: 65-72, 2004.
22. Johansson J-E, Brune M, Ekman T. The gut mucosa barrier is preserved during allogeneic, haematopoietic stem cell transplantation with reduced intensity conditioning. Bone Marrow Transplant, 28: 737-742, 2001.
23. Blijlevens NMA, Lutgens LCHW, Schattenberg AVMB, De Pauw BE. Citrulline: a potentially simple quantitative marker of intestinal epithelial damage following myeloablative therapy. Bone Marrow Transplant, 34: 193-196, 2004.
24. Vanclee A, Lutgens LC, Oving EB, et al. Keratinocyte growth factor ameliorates acute graft-versus-host disease in a novel nonmyeloablative haploidentical transplantation model. Bone Marrow Transplant, 36: 907-915, 2005.
25. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis, 34: 909-917, 2002.
26. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore), 78: 123-138, 1999.
27. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis, 175: 1459-1466, 1997.
28. Thursky K, Byrnes G, Grigg A, et al. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant, 34: 115-121, 2004.
29. Hagen EA, Stern H, Porter D, et al. High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin Infect Dis, 36: 9-15, 2003.
30. Ljungman P, Brand R, Einsele H, et al. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood, 102: 4255-4260, 2003.
31. Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant, 31: 145-155, 2003.
32. Robak T, Kasznicki M. Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia. Leukemia, 16: 1015-1027, 2002.
33. Thursky KA, Worth LJ, Seymour JF, et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br J Haematol, 132: 3-12, 2006.
34. Gavalda J, Len O, San JR, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis, 41: 52-59, 2005.
35. Meersseman W, Vandecasteele SJ, Wilmer A, et al. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med, 170: 621-625, 2004.
36. Holler E, Rogler G, Herfarth H, et al. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood, 104: 889-894, 2004.
37. Holler E, Rogler G, Brenmoehl J, et al. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: Effect on long term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood, Jan 19 2006 [Epub ahead of print].
38. Abreu MT, Fukata M, Arditi M. TLR signaling in the gut in health and disease. J Immunol, 174: 4453-4460, 2005.
39. Verburg M, Renes IB, van Nispen DJPM, et al. Specific responses in rat small intestinal epithelial mRNA expression and protein levels during chemotherapeutic damage and regeneration. J Histochem Cytochem, 50: 1525-1536, 2002.
40. Lorenz E, Schwartz DA, Martin PJ, et al. Association of TLR4 mutations and the risk for acute GVHD after HLA-matched-sibling hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 7: 384-387, 2001.
41. Kallianpur AR. Genomic screening and complications of hematopoietic stem cell transplantation: has the time come? Bone Marrow Transplant, 35: 1-16, 2005.
42. Dickinson AM, Middleton PG, Rocha V, et al. Genetic polymorphisms predicting the outcome of bone marrow transplants. Br J Haematol, 127: 479-490, 2004.
43. Mullighan CG, Heatley S, Doherty K, et al. Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood, 99: 3524-3529, 2002.
44. Horiuchi T, Gondo H, Miyagawa H, et al. Association of MBL gene polymorphisms with major bacterial infection in patients treated with high-dose chemotherapy and autologous PBSCT. Genes Immun, 6: 162-166, 2005.
45. Tamouza R, Neonato MG, Busson M, et al. Infectious complications in sickle cell disease are influenced by HLA class II alleles. Hum Immunol, 63: 194-199, 2002.
46. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis, 36: 1103-1110, 2003.
47. Costa SF, Miceli MH, Anaissie EJ. Mucosa or skin as source of coagulase-negative staphylococcal bacteraemia? Lancet Infect Dis, 4: 278-286, 2004.
48. Razonable RR, Litzow MR, Khaliq Y, et al. Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis, 34: 1469-1474, 2002.
49. Zhang X, McDaniel AD, Wolf LE, et al. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis, 181: 664-670, 2000.
50. Rees JR, Pinner RW, Hajjeh RA, et al. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. Clin Infect Dis, 27: 1138-1147, 1998.
51. VandenBergh MF, Verweij PE, Voss A. Epidemiology of nosocomial fungal infections: invasive aspergillosis and the environment. Diagn Microbiol Infect Dis, 34: 221-227, 1999.
52. Groll AH, Shah PM, Mentzel C, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect, 33: 23-32, 1996.
53. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis, 33: 641-647, 2001.
54. Munoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis, 40: 1625-1634, 2005.
55. Martino R, Salavert M, Parody R, et al. Blastoschizomyces capitatus infection in patients with leukemia: report of 26 cases. Clin Infect Dis, 38: 335-341, 2004.
56. Nucci M, Marr KA, Queiroz-Telles F, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis, 38: 1237-1242, 2004.
57. Husain S, Munoz P, Forrest G, et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis, 40: 89-99, 2005.
58. Lyke KE, Miller NS, Towne L, Merz WG. A case of cutaneous ulcerative alternariosis: rare association with diabetes mellitus and unusual failure of itraconazole treatment. Clin Infect Dis, 32: 1178-1187, 2001.
59. Hobson RP. The global epidemiology of invasive Candida infections - is the tide turning? J Hosp Infect, 55: 159-168, 2003.
60. Tortorano AM, Peman J, Bernhardt H, et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis, 23: 317-322, 2004.
61. Uzun O, Ascioglu S, Anaissie EJ, Rex JH. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis 32: 1713-1717, 2001.
62. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the I nvasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis, 28: 1071-1079, 1999.
63. Malani A, Hmoud J, Chiu L, et al. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis, 41: 975-981, 2005.
64. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis, 181: 309-316, 2000.
65. Doebbeling BN, Stanley GL, Sheetz CT, et al. Comparative efficacy of alternative hand-washing agents in reducing nosocomial infections in intensive care units. N Engl J Med, 327: 88-93, 1992.
66. Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet, 356: 645-649, 2000.
67. Boivin G, Goyette N, Gilbert C, et al. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl Infect Dis, 7: 166-170, 2005.
68. Beisel CE, Morens DM. Variant Creutzfeldt-Jakob disease and the acquired and transmissible spongiform encephalopathies. Clin Infect Dis, 38: 697-704, 2004.
69. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med, 142: 979-995, 2005.
70. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med, 353: 977-987, 2005.
71. Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med, 353: 988-998, 2005.
72. Martino R, Subira M. Invasive fungal infections in hematology: new trends. Ann Hematol 81: 233-243, 2002.
73. Trick WE, Fridkin SK, Edwards JR, et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis, 35: 627-630, 2002.
74. Bennett JE, Izumikawa K, Marr KA. Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob Agents Chemother, 48: 1773-1777, 2004.
75. Kibbler CC, Seaton S, Barnes RA, et al. Management and outcome of bloodstream infections due to Candida species in England and Wales. J Hosp Infect, 54: 18-24, 2003.
76. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med, 350: 950-952, 2004.
77. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis, 191: 1350-1360, 2005.
78. Pagano L, Offidani M, Fianchi L, et al. Mucormycosis in hematologic patients. Haematologica, 89: 207-214, 2004.
79. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis, 41: 634-653, 2005.
80. Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw, 3: 557-571, 2005.
81. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol, 23: 1178-1184, 2005.
82. Ellis M, Zwaan F, Hedstrom U, et al. Recombinant human interleukin 11 and bacterial infection in patients with haemological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. Lancet, 361: 275-280, 2003.
83. Antin JH, Weisdorf DJ, Neuberg D, et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood, 100: 3479-3483, 2002.
84. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med, 351: 2590-2598, 2004.
85. Gratwohl A, Brand R, Frassoni F, et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant, 36: 757-569, 2005.